BPI23-011: Real-World Study of First-Line Treatment Patterns in HR+/HER2– Metastatic Breast Cancer (MBC) at a Tertiary Care Cancer Institute

Authors:
Yolcar Chamorro Miami Cancer Institute, Miami, FL

Search for other papers by Yolcar Chamorro in
Current site
Google Scholar
PubMed
Close
 MS
,
Manmeet S. Ahluwalia Miami Cancer Institute, Miami, FL

Search for other papers by Manmeet S. Ahluwalia in
Current site
Google Scholar
PubMed
Close
 MD, MBA
,
Muni B. Rubens Miami Cancer Institute, Miami, FL

Search for other papers by Muni B. Rubens in
Current site
Google Scholar
PubMed
Close
 MBBS, PhD, MPH
,
Siddhartha A. Venkatappa Miami Cancer Institute, Miami, FL

Search for other papers by Siddhartha A. Venkatappa in
Current site
Google Scholar
PubMed
Close
 MBBS, MPH
,
Andrew J. Belli COTA, Inc.

Search for other papers by Andrew J. Belli in
Current site
Google Scholar
PubMed
Close
 MPH
,
Nicholas Ritter COTA, Inc.

Search for other papers by Nicholas Ritter in
Current site
Google Scholar
PubMed
Close
 MBA
,
Ching-Kun Wang COTA, Inc.

Search for other papers by Ching-Kun Wang in
Current site
Google Scholar
PubMed
Close
 MD
,
Reshma L. Mahtani Miami Cancer Institute, Miami, FL

Search for other papers by Reshma L. Mahtani in
Current site
Google Scholar
PubMed
Close
 DO
, and
Ana Sandoval Leon Miami Cancer Institute, Miami, FL

Search for other papers by Ana Sandoval Leon in
Current site
Google Scholar
PubMed
Close
 MD
Full access

Background: A cyclin-dependent kinase inhibitor (CDK 4/6i) plus endocrine therapy (ET) is considered standard of care first-line (1L) treatment for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) MBC without visceral crisis. A recent retrospective claims analysis showed that the combination of ET-CDK 4/6i was underutilized at our institution as 1L therapy; notably that no patients over age 66 received the combination in 2018. We sought to confirm this finding using clinical real-world data (RWD). Methods: Records from patients with HR+ HER2- MBC treated in the 1L setting at our institution between 2017 and 2019 were abstracted by COTA and identified using COTA Real-world Analytics (RWA), an analytics platform enabling rapid investigation of longitudinal RWD. A subsequent confirmatory IRB-approved retrospective chart review was conducted. We excluded patients who initiated treatment at an outside facility, were seen only in the inpatient setting, or where treatment was not initiated by a medical oncologist at our institution. The treatment groups were divided into four cohorts: ET-CDK 4/6i, ET alone, chemotherapy, and no therapy. Descriptive statistics were used to describe 1L treatments and associated variables. Results: 135 patients with HR+ HER2- MBC were included. Median age was 62.2 y (30-99 y). The most common treatments were ET-CDK 4/6i (55%), chemotherapy (21%), and ET (17%). Seven percent of patients did not receive any treatment (patient refusal, hospice, or death). Rationale for chemotherapy included visceral crisis (34%), oligometastatic disease with chemotherapy administered as curative intent (24%), and low estrogen receptor expression (14%). Of the patients that received chemotherapy, 76% had visceral metastasis. There was an increase in the number of patients that received ET-CDK 4/6i from 45% in 2017 to 62% in 2019 (Figure 1). In patients age over 66 years, approximately 62% of patients received ET-CDK4/6i. Conclusions: Our study showed an increase in the utilization of CDK 4/6i at our institution from 2017-2019 at rates similar to national trends. This finding is significantly different from what was observed in a previous claims analysis. Our findings demonstrate the value of clinical RWD in understanding real-world treatment patterns. Future research will further leverage RWD to investigate deep clinical questions including treatment response, sequencing and patient outcomes.

Figure 1.
Figure 1.

First-Line Treatment by Category

Citation: Journal of the National Comprehensive Cancer Network 21, 3.5; 10.6004/jnccn.2022.7212

Corresponding Author: Andrew J. Belli, MPH

Email: andrewbelli@cotahealthcare.com
  • Collapse
  • Expand
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1330 909 32
PDF Downloads 0 0 0
EPUB Downloads 0 0 0